发明申请
- 专利标题： NADPH OXIDASE 4 INHIBITORS
-
申请号： US16777308申请日： 2020-01-30
-
公开(公告)号： US20200165235A1公开(公告)日： 2020-05-28
- 发明人: Hamed Aissaoui , Martin Bolli , Christoph Boss , Sylvia Richard-Bildstein , Patrick Sieber
- 申请人： ACTELION PHARMACEUTICALS LTD
- 申请人地址： CH Allschwil
- 专利权人： ACTELION PHARMACEUTICALS LTD
- 当前专利权人： ACTELION PHARMACEUTICALS LTD
- 当前专利权人地址： CH Allschwil
- 优先权： com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@90108b8
- 主分类号： C07D413/12
- IPC分类号： C07D413/12 ; C07D491/107 ; C07D471/10 ; C07D417/14 ; C07D417/12 ; C07D413/14 ; A61P35/04 ; A61P11/00 ; C07D277/62 ; C07D263/58 ; C07D263/54
摘要：
The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
公开/授权文献
- US11136317B2 NADPH oxidase 4 inhibitors 公开/授权日：2021-10-05
信息查询
